tiprankstipranks
Trending News
More News >
Karyopharm Therapeutics (KPTI)
NASDAQ:KPTI
US Market

Karyopharm Therapeutics (KPTI) Income Statement

Compare
1,206 Followers

Karyopharm Therapeutics Income Statement

Last quarter (Q3 2025), Karyopharm Therapeutics's total revenue was $44.04M, an increase of 13.57% from the same quarter last year. In Q3, Karyopharm Therapeutics's net income was $-33.13M. See Karyopharm Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 145.24M$ 146.03M$ 157.07M$ 209.82M$ 108.08M
Gross Profit
$ 139.23M$ 141.09M$ 151.86M$ 206.42M$ 105.38M
Operating Expenses
$ 258.67M$ 270.63M$ 294.06M$ 304.69M$ 277.23M
Depreciation and Amortization
$ 340.00K$ 530.00K$ 621.00K$ 789.00K$ 972.00K
EBITDA
$ -38.60M$ -118.42M$ -139.31M$ -96.98M$ -167.85M
Operating Income
$ -119.44M$ -129.54M$ -142.20M$ -98.27M$ -171.85M
Other Income/Expenses
$ 43.08M$ -13.24M$ -22.72M$ -25.55M$ -24.11M
Pretax Income
$ -76.36M$ -142.78M$ -164.92M$ -123.82M$ -195.96M
Net Income
$ -76.42M$ -143.10M$ -165.29M$ -124.09M$ -196.27M
Per Share Metrics
Basic EPS
$ -9.41$ -18.79$ -30.28$ -24.75$ -40.87
Diluted EPS
$ -9.41$ -18.79$ -30.28$ -24.75$ -40.87
Weighted Average Shares Outstanding
8.12M 7.61M 5.46M 5.01M 4.80M
Weighted Average Shares Outstanding (Diluted)
8.12M 7.61M 5.46M 5.01M 4.80M
Currency in USD

Karyopharm Therapeutics Earnings and Revenue History